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and thus avoid the disadvantages inherent in the use of

NASAL DOSAGE FORMS CONTAINING
NATURAL FEMALE SEX HORMONES

‘

potentially unsafe synthetic estrogens and progestins.

It is yet a further object of the present invention to
provide a novel method and novel dosage forms con
This application is a continuation, of application Ser. 5
taining 17 B-estradiol or progesterone useful in the
No.l54,995, ?led May 30, 1980 now US. Pat. No.
treatment of conditions such as menopause, menstrual
4,315,925.
disorders, etc. which are known to respond to adminis
BACKGROUND OF THE INVENTION
tration of a natural or synthetic female sex hormone.
10
1. Field of the Invention
The foregoing objects are achieved by nasal adminis
The present invention relates to a novel method of
tration of l7 B-estradiol (if desired, in the form of one of
administering the natural female sex hormones, 17 B
its estrogenically effective esters) and/or progesterone.
estradiol and progesterone, and to novel dosage forms
According to the invention, these natural female sex
containing those compounds, singly or in combination,
hormones are administered via a novel nasal dosage
which are adapted for nasal administration.
form, i.e., a solution, suspension, ointment or gel
2. Description of the Prior Art
adapted for nasal administration.
17 B-estradiol is the most potent natural estrogen

found in human beings and is the major secretory prod
uct of the ovary. It is readily oxidized in the body to
estrone, which in turn can be hydrated to estriol. These 20

transformations take place mainly in the liver, where

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a semi-logarithmic plot of mean blood levels

of progesterone after intravenous (IV), nasal and in

there is free interconversion between estrone and estra
diol. All three of these natural estrogens are excreted in
the urine as glucuronides and sulfates, along with a host

traduodenal/oral (ID) administration of a dose of 50 pg
of progesterone per rat.
of related, minor products in water-soluble complexes. 25 FIG. 2 is a graph showing the area under the curve as
a function of dose for the intravenous (IV) and nasal
It is widely known that, following oral administration
of micronized l7 B-estradiol (E2), the incremental cir
routes of progesterone administration (50 pg, 100 pg

culation estrogen is principally the less active species

and 150 pg dosage levels).

estrone (E1), which reaches a peak concentration many
times greater than that of E2. The conversion of E1 to

FIG. 3 is a semi-logarithmic plot of mean blood levels

of total unconjugated estrogens (TUE) following intra

E1 and subsequently to other metabolites takes place
during absorption from the intestine and passage
through the liver. This extensive metabolism greatly

venous (IV), nasal and intraduodenal/oral (ID) admin
istration of a dose of 10 pg of 17 B-estradiol per rat.
FIG. 4 is a semi-logarithmic plot of mean blood levels

limits the oral effectiveness of the natural estrogens and
their esters. Indeed, because of their limited oral effl
cacy, l7 B-estradiol and its esters are generally adminis

of estradiol (E2) following intravenous (IV), nasal and
intraduodenal/oral (ID) administration of a dose of 10

tered by intramuscular injection.
Progesterone is the active natural progestin which

pg of l7 B-estradiol per rat.

a

FIG. 5 is a semi-logarithmic plot of mean blood levels

occurs in the corpus luteum, placenta and adrenal cor
tex. It is not effective by mouth because of its rapid 40 of estrone (E1) following intravenous (IV), nasal and
intraduodenal/oral (ID) amdinistration of a dose of 10
metabolism in the intestinal epithelium and in the liver,

pg of 17 B-estradiol per rat.

and is therefore only administered intramuscularly.
Because of their limited oral effectiveness, these natu
ral female sex hormones have not found utility in oral

contraceptives. Instead, only active synthetic estrogens
and progestins have been prepared and are used for

contraceptive purposes. The synthetic derivatives have ‘

also in many cases replaced the natural substances in the
treatment of menopause, threatened abortion, etc. How

DETAILED DESCRIPTION OF THE
INVENTION

45

The word “progesterone" as used herein means

pregn-4-ene-3,20-dione, i.e., the compound of the for
mula

ever, the synthetic derivatives are, generally speaking,
much more likely to cause toxic side effects than are the

relatively safe natural hormones.
SUMMARY OF THE INVENTION
In view of the foregoing, it is apparent that a serious
need exists for the improved delivery of the natural
female sex hormones. Thus, it is an object of the present
invention to provide novel dosage forms and a novel

method of administering l7 B-estradiol and progester
one, separately or in combination, which will provide
greatly enhanced bioavailability as compared to oral
administration, while at the same time providing rela
tive ease of administration when compared to intramus

cular injection.

0%
and is intended to include progesterone derived from
natural sources as well as that made synthetically.

The word “17 B-estradiol” as used herein is intended

to encompass any pharmaceutically acceptable, estro
It is a further object of the present invention to pro 65
genically active form of 17 B-estradiol, i.e., estra
vide a novel contraceptive method and novel composi
l,3,5(l0)-triene-3,17 B-diol itself, which has the formula
tions for accomplishing same which utilize the natural
female sex hormones, l7 B-estradiol and progesterone,

4,383,993
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TABLE I

AREA UNDER THE CURVE AFTER INTRAVENOUS,
NASAL AND INTRADUODENAL ADMINISTRATION
OF PROGESTERONE IN RATS

Dose
pg/rat
50
HO
100

and which may be extracted from natural sources or
made synthetically, or one of its 3- or l7-monoesters or

150

3,17-diesters. By way of illustration, suitable esters of 17
B-estradiol for purposes of the present invention include

AUQQ, ng. min/ml
Nasal

1612.2‘

1659.0

t 80.8

i 109.2

3520.0

3599.0

i 491.0

: 621.4

4480.2

4798.9

1 466.4

1 188.5

ID

Nasal
IV

ID
IV

19.0

1.029

0.012

—

1.022

-—

-

1.07]

-—

i 4.6

‘mean : SE(n = 4-6).“

3-monoesters such as estradiol benzoate and estradiol

By using the two tailed t-test, it can be shown that the
area under the curve following intravenous and nasal
administration at each dose were not signi?cantly dif
ferent, even at the 0.001 level. However, as can be seen

3-acetate; l7-monoesters such as estradiol cypionate,

estradiol l7-propionate, estradiol l7-acetate, estradiol

l7-heptan0ate (estradiol enanthate), estradiol 17
undecanoate (estradiol undecylate) and estradiol l7-val
erate; and 3,17-diesters such as estradiol dipropionate

IV

20 from Table I, oral administration of 50 pg resulted in

and estradiol diacetate.

bioavailability equal to only 1.2% that of an equivalent
dose given intravenously. Also from Table I, it can be

According to the present invention, it has surpris
ingly been found that 17 B-estradiol and progesterone

seen that the nasal bioavailability of progesterone at the
50 pg dosage level was 85.75 times greater than the oral

can be administered nasally with results considerably
superior to those obtained with oral administration. The

bioavailability.

following studies were undertaken to examine the bi

very rapidly absorbed from the nasal mucosa; thus, at
thei50 pg dosage level, the peak plasma level was at~
tained in less than 7 minutes after instillation of the nose

oavailability of progesterone and 17 B-estradiol from
nasal solution in comparison with the bioavailability of
these drugs when administered orally and intrave

nously.

It can also be seen from FIG. 1 that progesterone is

drops.
FIG. 2 shows the area under the curve as a function

Sprague-Dawley male rats, each weighing about 270

of dose for the intravenous and nasal routes. As can be
grams, were used in the progesterone study. For nasal
seen from FIG. 2, for both IV and nasal routes of ad
administration, the rats were anesthetized using sodium 35 ministration the area under the curve (AUC) was di

pentobarbital (50 mg/kg) and the drug was adminis

agent, according to the procedure described by Hirai et
al, the 98th Annual Meeting of Pharmaceutical Society
of Japan, Okayama, April 1978, eitcept that the end of

rectly proportional to the dose administered.
The study described above indicates that progester
one is rapidly absorbed from the nasal mucosa into the
systemic circulation without ?rst pass metabolism. It is
further apparent from this study that the bioavailability
of progesterone when administered nasally is equivalent
to the bioavailability of the drug where administered
intravenously and vastly superior to its bioavailability

the tube leading from the esophagus to the nasal cavity 45

by the oral route.

tered to the nasal cavity by means of a micropipet at

dosage levels of 50 pg, 100 pg and 150 pg/‘rat of [4

14C]-progesterone (~8.5 pCi/rat) in 0.1 ml of isotonic
saline containing l—2% Tween 80 as a solubilizing

was closed and the drug was administered to the nostrils
which were then closed with an adhesive agent. For
oral (intraduodenal) administration, the rats were anes
thetized and the abdomen of each rat was opened
through a rnidline incision and a 50 pg/rat dose of the

’

A study similar to that described above was under—

taken to study the bioavailability of nasally adminis
tered l7 B-estradiol vis-a-vis its bioavailability via intra
venous and oral routes. Sprague-Dawley male rats,

each weighing approximately 270 grams, were given
drug ([4-l4C]-progesterone in 0.1 ml isotonic saline with
dosages of 5 pg, 10 pg and 20 pg/rat of [6,7-3I-I] l7
l-2% Tween 80) was injected directly through the
B-estradiol in 0.1 ml isotonic saline containing 1%
duodenum. For intravenous administration, the rats
Tween 80 via the intravenous, nasal and intraduodenal
were anesthetized and the drug was injected through 55 routes, according to the procedures described above
the femoral vein at dosage levels of 50 pg, 100 pg and
with respect to the progesterone study. Blood samples
150 pg/ rat of [4~l4C]-progesterone in 0.1 ml of isotonic
were taken periodically as described in the progester
saline containing l—2% Tween 80. Blood was sampled
one study and assayed for estradiol (E2), estrone (E1)
periodically from the femoral aorta after IV and nasal
administration, and from the tail vein after ID adminis
tration. Blood levels of progesterone were determined

by thin layer chromotography.

and total unconjugated estrogens (TUE).
FIGS. 3, 4 and“ 5 show typical plots of the mean blood
levels of TUE, E2 and E1 following intravenous, nasal
and oral administration of 10 pg of 17 B-estradiol per
rat. These ?gures clearly show that 17. B-estradiol is

FIG. 1 shows the mean blood levels of progesterone
for the study described above after intravenous, nasal 65 rapidly absorbed by the nasal mucosa.
and oral administration of a dose of 50 pg/rat, while
Table I below summarizes the area under the curve for
the three routes of administration at the various doses.

Table II below shows the area under the curve for the

three routes of administration at the various dosage

levels of 17 B-estradiol.

4,383,993
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6

estrogen alone is to be administered for a part of th

TABLE 11

cycle.

AREA UNDER THE CURVE AND BIOAVAILABILITY

OF ADMINISTRATION AT THE VARIOUS DOSES

DOSE ROUTE 0F
)tG/RAT ADMINISTRATION
5

IV
NASAL

Augq.No.M1N.ML—1
TUE
E;
E(
555.5
331.0

(0.606)
ORAL

119.2

(0.215)
10

iv
NASA].

954.6
761.2

ORAL

314.2

(0.791)
(0.329)
20

iv
NASAL

1936.9
1777.2

(0.9115)
ORAL

786.9

(0.406)

2903
146.8

(1.657)

11.1

10.6

(0.038)

(0.199)

609.0
415.2

(2.013)

19.1

l6.8

(0.031)

estrogenic component is not. This type of composition
may be used in the treatment of conditions for which

natural or syntheic progestins have previously been
used, tag, in threatened or habitual abortion, endometri
osis and menstrual disorders such as dysmenorrhea and
(0

83.5
173.1

(0.682)
1062.6
891.8

5

53.4
88.5

(0.505)

‘

In another embodiment of the present invention, pro
gesterone is present in the nasal dosage form, but the

OF TUE, E; AND E) FOR THE DIFFERENT ROUTES

functional uterine bleeding, in inhibiting ovulation and
possibly as a “progestin only" continuously adminis
tered contraceptive (analogous to “minipill" type of
oral contraceptives).
Suitable nontoxic pharmaceutically acceptable nasal

(0.201) 15 carriers for use in the compositions of the present inven

l64.4
354.0

(0.339)

(2.153)

53.4

42.4

(0.050)

(0.255)

tion will be apparent to those skilled in the art of nasal
pharmaceutical formulations. For those not skilled in
the art, reference is made to the text entitled “REM

INGTON‘S PHARMACEUTICAL SCIENCES", 4th
edition, 1970. Obviously, the choice of suitable carriers

( ) RATIO VS. IV

will depend on the exact nature of the particular nasal
As can be seen from Table II, the TUE bioavailability

dosage form desired, e.g. whether the active in

after nasal administration ranged from 60.6% to 91.8%

gredient(s) is/are to be formulated into a nasal solution

that of the correspondng doses given intravenously,

(for use as drops or as a spray), a nasal suspension, a
while oral administration resulted in TUE bioavailabil 25 nasal ointment or a nasal gel, as well as on the identity

ity that ranged from only 21.5% to 40.6% that of the

of the active ingredient(s). Preferred nasal dosage forms

corresponding doses given intravenously. Thus, nasal

are solutions, suspensions and gels, which contain a

bioavailability of TUE was from 2.26 to 2.83 times

major amount of water (preferably puri?ed water) in
greater than oral bioavailability. Even more signi?
addition to the active ingredient(s). Minor amounts of
cantly, Table [I further shows that the E; bioavailability 30 other ingredients such as pH adjusters (e.g., a base such
after nasal administration ranged from 50.5% to 83.9%
as NaOH), emulsi?ers or dispersing agents (cg. poly

that of the corresponding doses given intravenously,

oxyethylene 20 sorbitan mono-oleate), buffering agents,
preservatives, wetting agents and jelling agents (e.g.

while oral administration resulted in E2 bioavailabilities
that ranged from only 3.1% to 5.0% that of the corre

sponding doses given intravenously. Thus, nasal bi

methylcellulose) may also be present. Also, a sustained
35

oavailability of E2 was from l3.23 to 21.74 times greater

than oral bioavailability.
The studies described above indicate that progester
one 17 B-estradiol are rapidly absorbed from the nasal
mucosa into systemic blood without extensive intestinal

release composition, e.g. sustained release gel, readily
can be prepared by employing l7 B-estradiol in one of
its relatively insoluble, long-acting forms, e.g. as estra

diol cypionate.
Examples of the preparation of typical nasal composi
tions are not set forth below. However, it is to be under

or ?rst pass metabolism.

stood that these examples are given by way of illustra

Progesterone and I7 B-estradiol can be conveniently
administered nasally to warm-blooded animals by for
mulating them, singly or in combination, into a nasal
dosage form comprising the selected natural female sex 45
hormone(s) and a nontoxic pharmaceutically acceptable
nasal carrier therefor. As indicated earlier, any pharma

tion only and are not to be construed as limiting the
invention either in spirit or in scope as many modi?ca

ceutically acceptable, estrogenically active form of 17
B-estradiol can be employed in the nasal form, e.g., the

tions both in materials and in methods will be apparent
to those skilled in the art.

EXAMPLE I

25 milligrams of progesterone and 5 milligrams of 17
?-estradiol were combined with 10 milligrams of

diol itself or one of its esters. In a preferred embodiment

Tween 80. That mixture was then combined with a

of the invention, both progesterone and a suitable form
of 17 B-estradiol are present in the nasal dosage form,

quantity of isotonic saline sufficient to bring the total
volume to 50 milliliters. The solution was sterilized by

which can be employed in preventing conception, for
being passed through a 0.2 micron Millipore ?lter.
example, by administration in a cyclic manner anala
EXAMPLE 2
gous to that used for the oral contraceptives.
55
In another embodiment, the estrogenic component,
50 milligrams of progesterone and 5 milligrams of 17
i.e., one of the suitable forms of 17 Bestradiol, is present
B-estradiol were combined with 10 milligrams of
but progesterone is not; this type of composition may be
Tween 80. That mixture was then combined with a
used for any of a variety of conditions for which natural
quantity of isotonic saline sufficient to bring the total
or synthetic estrogens have previously been adminis 60 volume of the solution to 50 milliliters. The solution was
tered, e.g., to control menopausal symptoms, hot ?ushes
sterilized by being passed through a 0.2 micron Mil
and later osteoporosis; also in atropic vaginitis, and to
lipore filter.
relieve postpartum breast en gorgement, dysmenorrhea,
EXAMPLE 3
amenorrhea, memorrhagia, and as substitution therapy
in ovarian dwarfism; also to control prostatic carci 65 250 milliliters of isotonic saline were heated to 80° C.
noma, and possibly also as a “morning-after” contracep
and 1.50 grams of Methocel were added, with stirring.

tive. Also, the “estrogen only” nasal composition could

The resultant mixture was allowed to stand at room

be used in a sequential contraceptive regimen in which

temperature for 2 hours. Then, 50 milligrams of proges

7
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terone and 10 milligrams of 17 B-estradiol were mixed

4. A composition according to claim 2, wherein the

together with 10 milligrams of Tween 80. The steroid/
Tween mixture and a quantity of isotonic saline suffi
cient to bring the total volume to 500 milliliters were

of l7B-estradiol is estradiol benzoate.
5. A composition according to claim 2 wherein the

added to the gel and thoroughly mixed.

pharmaceutically acceptable, estrogenically active form

pharmaceutically acceptable, estrogenically active form

of 17B-estradiol is estradiol cypionate.

EXAMPLE 4

6. A composition according to claim 2, wherein the

pharmaceutically acceptable, estrogenically active form

Repetition of the procedure of Example 1, but omit

of 17,6-estradiol is estradiol dipropionate.

ting the 25 milligrams of progesterone, affords an “es

trogen only” nasal composition.

10

EXAMPLE 5

Repetition of the procedure of Example 2, but omit
ting the 5 milligrams of l7B-estradiol, affords a “proges
terone only " nasal composition.

EXAMPLE 6

Substitution of an equivalent quantity of estradiol

benzoate, estradiol cypionate, estradiol dipropionate,
estradiol enanthate or estradiol l7-valerate for the 173

estradiol employed in Example 1, 2, 3 or 4 and repeti
tion of the procedures there detailed affords other nasal
compositions according to the invention.
Naturally, the therapeutic dosage range for nasal
administration of the compositions of the present inven
tion will vary with the size of the patient, the condition
for which the composition is administered and the par~
ticular form of l7B-estradiol employed (when the com
position is an “estrogen only” or estrogen/progestin
combination). A typical dose of a combination form for

7. A composition according to claim 2, wherein the

pharmaceutically acceptable, estrogenically active form
of l7B-estradiol is estradiol enanthate.
8. A composition according to claim 2, wherein the

pharmaceutically acceptable, estrogenically active form
of l7B-estradiol is estradiol l7-valerate.
9. A composition according to claim 1, said composi
tion comprising a nasal ointment.
10. A composition according to claim 1, said compo
sition comprising a nasal gel.
11. A composition according to claim 10, said compo
sition comprising a sustained release nasal gel.
12. A composition according to claim 1, containing
from about 10 pg to 5000 pg of progesterone and from
about 10 pg to 500 pg of a pharmaceutically acceptable,

estrogenically active form of l7B-estradiol.
13. A pharmaceutically acceptable nasal composition,
in dosage unit form, for nasal administration to elicit a

systemic progestational response in a mammal, said

composition consisting essentially of, per nasal dosage
unit, a systemically therapeutically effective progesta

use as a contraceptive would be from 10 pg to 500 pg of

tional amount of progesterone and a nontoxic pharma

l7B-estradiol and from 10 pg to 5000 pg of progester
one, administered nasally once daily. The quantity of
nasal dosage form needed to deliver the desired dose

ceutically acceptable nasal carrier therefor, said compo

will of course depend on the concentration of the active

sition comprising a nasal ointment.

sition comprising a nasal ointment or a nasal‘gel.

14. A composition according to claim 13, said compo

15. A composition according to claim 13, said compo
ingredients in the composition. For example, when a
sition comprising a nasal gel.
composition as described in Example 2 above is used to
16. A pharmaceutically acceptable nasal composition,
deliver a typical dose of 0.5 mg of progesterone, the
volume of solution which would be needed would be 40 in dosage unit form, for nasal administration to elicit a
systemic estrogenic response in a mammal, said compo
approximately 0.5 ml.
sition consisting essentially of, per nasal dosage unit, a
While the invention has been described in terms of

various preferred embodiments, the skilled artisan will
appreciate that various modi?cations, substitutions,
omissions and additions may be made without departing
from the spirit thereof. Accordingly, it is intended that
the scope of the present invention be limited solely by

the scope of the following claims.
What is claimed is:

1. A pharmaceutically acceptable nasal composition,
in dosage unit form, for nasal administration to a female

mammal for the purpose of mammalian contraception,

said composition consisting essentially of, per nasal unit,
a systemically effective contraceptive amount of a com
bination of progesterone and a pharmaceutically ac 55

ceptable, estrogenically active form of l7B-estradiol,
together with a nontoxic pharmaceutically acceptable

systemically

therapeutically

effective

estrogenic

amount of a pharmaceutically acceptable, estrogeni
cally active form of l7B-estradiol and a nontoxic phar
maceutically acceptable nasal carrier therefor, said
composition comprising a nasal ointment or a nasal gel.

17. A composition according to claim 16, wherein the

pharmaceutically acceptable, estrogenically active form
of l7B-estradiol is selected from the group consisting of
l7B-estradiol, 3-monoesters of l7B-estradiol, l7-mono
esters of l7B-estradiol and 3,17-diesters of l7B- estra
diol.
18. A composition according to claim 17, wherein the

pharmaceutically acceptable, estrogenically active form
of l7B-estradiol is l7B-estradiol.
19. A composition according to claim 17, wherein the

nasal carrier therefor, said composition comprising a

pharmaceutically acceptable, estrogenically active form

nasal ointment or a nasal gel.

of l7B-estradiol is estradiol benzoate.
20. A composition according to claim 17, wherein the

2. A composition according to claim 1, wherein the 60

pharmaceutically acceptable, estrogenically active form

pharmaceutically acceptable, estrogenically active form

of 17B-estradiol is estradiol cypionate.
of l7B-estradiol is selected from the group consisting of
21. A composition according to claim 17, wherein the
l7B~estradiol, 3-monoesters of l7B-estradiol, l7-mono
pharmaceutically acceptable, estrogenically active form
esters of l7B-estradiol and 3,17-diesters of 173
65 of Hit-estradiol is estradiol dipropionate.
estradiol.
22. A composition according to claim 17, wherein the
3. A composition according to claim 2, wherein the

pharmaceutically acceptable, estrogenically active form

pharmaceutically acceptable, estrogenically active form

of l7B-estradiol is l7B-estradiol.

of l7B-estradiol is estradiol enanthate.

9
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23. A composition according to claim 17, wherein the

25. A composition according to claim 16, said compo

pharmaceutically acceptable, estrogenically active form
of l7B-estradiol is estradiol l7-valerate.
24. A composition according to claim 16, said compo-

sition comprising a nasal gel.
26. A composition according to claim 25, said compo

sition comprising a nasal ointment.

sition comprising a sustained release nasal gel.
5
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